Evidence map›Paper›PMID 34696254›Full record

ArticleVaccines2021

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.

Myron J Levin, Victoria Divino, Drishti Shah, Mitch DeKoven, Joaquin Mould-Quevedo, Stephen I Pelton, Maarten J Postma

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Journal of preventive medicine and hygiene · 2025
    Article
  3. Article
  4. [Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Myron J LevinDepartments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.
Victoria DivinoReal World Solutions, IQVIA, Falls Church, VA 22042, USA.
Drishti ShahReal World Solutions, IQVIA, Falls Church, VA 22042, USA.ORCID 0000-0002-5866-7743
Mitch DeKovenReal World Solutions, IQVIA, Falls Church, VA 22042, USA.
Joaquin Mould-QuevedoGlobal Pricing & Health Economics, Seqirus USA Inc., Summit, NJ 07901, USA.
Stephen I PeltonDepartment of Pediatrics, Boston University Schools of Medicine, Boston, MA 02118, USA.
Maarten J PostmaDepartment of PharmacoTherapy, Epidemiology & Economics (PTE2), Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
IQVIA (United States) · USBoston University · USSeqirus (United States) · USUniversity Medical Center Groningen · NLUniversity of Colorado Anschutz Medical Campus · US

Funding

Seqirus USA Inc. N/A
6 · The paper itself

Abstract

The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019-2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (

Indexed as

adjuvanted influenza vaccineeconomic outcomesinfluenzaolder adultsrelative vaccine effectivenessretrospective studies

Identifiers

PMID34696254
PMCPMC8540032
OpenAlexW3203709630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.